Literature DB >> 33423300

Germline APOBEC3B deletion increases somatic hypermutation in Asian breast cancer that is associated with Her2 subtype, PIK3CA mutations, and immune activation.

Jia-Wern Pan1, Muhammad Mamduh Ahmad Zabidi1, Boon-Keat Chong1, Mei-Yee Meng1, Pei-Sze Ng1,2, Siti Norhidayu Hasan1, Bethan Sandey3, Saira Bahnu4, Pathmanathan Rajadurai4, Cheng-Har Yip2,4, Oscar M Rueda3, Carlos Caldas3,5,6, Suet-Feung Chin3, Soo-Hwang Teo1,2.   

Abstract

A 30-kb deletion that eliminates the coding region of APOBEC3B (A3B) is >5 times more common in women of Asian compared to European descent. This polymorphism creates a chimera with the APOBEC3A (A3A) coding region and A3B 3'UTR, and is associated with an increased risk for breast cancer in Asian women. Here, we explored the relationship between the A3B deletion polymorphism with tumour characteristics in Asian women. Using whole exome and whole transcriptome sequencing data of 527 breast tumours, we report that germline A3B deletion polymorphism leads to expression of the A3A-B hybrid isoform and increased APOBEC-associated somatic hypermutation. Hypermutated tumours, regardless of A3B germline status, were associated with the Her2 molecular subtype and PIK3CA mutations. Compared to non-hypermutated tumours, hypermutated tumours also had higher neoantigen burden, tumour heterogeneity and immune activation. Taken together, our results suggest that the germline A3B deletion polymorphism, via the A3A-B hybrid isoform, contributes to APOBEC-mutagenesis in a significant proportion of Asian breast cancers. In addition, APOBEC somatic hypermutation, regardless of A3B background, may be an important clinical biomarker for Asian breast cancers. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.

Entities:  

Year:  2021        PMID: 33423300     DOI: 10.1002/ijc.33463

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  5 in total

1.  Germline copy number variations in BRCA1/2 negative families: Role in the molecular etiology of hereditary breast cancer in Tunisia.

Authors:  Maroua Boujemaa; Yosr Hamdi; Nesrine Mejri; Lilia Romdhane; Kais Ghedira; Hanen Bouaziz; Houda El Benna; Soumaya Labidi; Hamza Dallali; Olfa Jaidane; Sonia Ben Nasr; Abderrazek Haddaoui; Khaled Rahal; Sonia Abdelhak; Hamouda Boussen; Mohamed Samir Boubaker
Journal:  PLoS One       Date:  2021-01-27       Impact factor: 3.240

2.  Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer.

Authors:  Liv B Gansmo; Nigar Sofiyeva; Merete Bjørnslett; Pål Romundstad; Kristian Hveem; Lars Vatten; Anne Dørum; Per E Lønning; Stian Knappskog
Journal:  Sci Rep       Date:  2021-12-06       Impact factor: 4.379

3.  Cancer Evo-Dev: A Theory of Inflammation-Induced Oncogenesis.

Authors:  Wenbin Liu; Yang Deng; Zishuai Li; Yifan Chen; Xiaoqiong Zhu; Xiaojie Tan; Guangwen Cao
Journal:  Front Immunol       Date:  2021-11-22       Impact factor: 7.561

4.  Tumor Infiltrating Lymphocytes in Multi-National Cohorts of Ductal Carcinoma In Situ (DCIS) of Breast.

Authors:  Sunil S Badve; Sanghee Cho; Xiaoyu Lu; Sha Cao; Soumya Ghose; Aye Aye Thike; Puay Hoon Tan; Idris Tolgay Ocal; Daniele Generali; Fabrizio Zanconati; Adrian L Harris; Fiona Ginty; Yesim Gökmen-Polar
Journal:  Cancers (Basel)       Date:  2022-08-13       Impact factor: 6.575

5.  Circ-ZEB1 promotes PIK3CA expression by silencing miR-199a-3p and affects the proliferation and apoptosis of hepatocellular carcinoma.

Authors:  Weiwei Liu; Lu Zheng; Rongguiyi Zhang; Ping Hou; Jiakun Wang; Linquan Wu; Jing Li
Journal:  Mol Cancer       Date:  2022-03-11       Impact factor: 27.401

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.